Literature DB >> 27189837

Urokinase links plasminogen activation and cell adhesion by cleavage of the RGD motif in vitronectin.

Valentina De Lorenzi1, Gian Maria Sarra Ferraris1, Jeppe B Madsen2, Michela Lupia3, Peter A Andreasen2, Nicolai Sidenius4.   

Abstract

Components of the plasminogen activation system including urokinase (uPA), its inhibitor (PAI-1) and its cell surface receptor (uPAR) have been implicated in a wide variety of biological processes related to tissue homoeostasis. Firstly, the binding of uPA to uPAR favours extracellular proteolysis by enhancing cell surface plasminogen activation. Secondly, it promotes cell adhesion and signalling through binding of the provisional matrix protein vitronectin. We now report that uPA and plasmin induces a potent negative feedback on cell adhesion through specific cleavage of the RGD motif in vitronectin. Cleavage of vitronectin by uPA displays a remarkable receptor dependence and requires concomitant binding of both uPA and vitronectin to uPAR Moreover, we show that PAI-1 counteracts the negative feedback and behaves as a proteolysis-triggered stabilizer of uPAR-mediated cell adhesion to vitronectin. These findings identify a novel and highly specific function for the plasminogen activation system in the regulation of cell adhesion to vitronectin. The cleavage of vitronectin by uPA and plasmin results in the release of N-terminal vitronectin fragments that can be detected in vivo, underscoring the potential physiological relevance of the process.
© 2016 The Authors.

Entities:  

Keywords:  RGD; cell adhesion; extracellular proteolysis; urokinase‐type plasminogen activator system; vitronectin

Mesh:

Substances:

Year:  2016        PMID: 27189837      PMCID: PMC4931562          DOI: 10.15252/embr.201541681

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


  52 in total

1.  Extracellular matrix remodeling by human granzyme B via cleavage of vitronectin, fibronectin, and laminin.

Authors:  Marguerite S Buzza; Laura Zamurs; Jiuru Sun; Catherina H Bird; A Ian Smith; Joseph A Trapani; Christopher J Froelich; Edouard C Nice; Phillip I Bird
Journal:  J Biol Chem       Date:  2005-04-19       Impact factor: 5.157

2.  Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.

Authors:  A Monks; D Scudiero; P Skehan; R Shoemaker; K Paull; D Vistica; C Hose; J Langley; P Cronise; A Vaigro-Wolff
Journal:  J Natl Cancer Inst       Date:  1991-06-05       Impact factor: 13.506

3.  Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor.

Authors:  E Rønne; N Behrendt; V Ellis; M Ploug; K Danø; G Høyer-Hansen
Journal:  FEBS Lett       Date:  1991-08-19       Impact factor: 4.124

4.  Site-directed mutagenesis of the arginine-glycine-aspartic acid in vitronectin abolishes cell adhesion.

Authors:  R C Cherny; M A Honan; P Thiagarajan
Journal:  J Biol Chem       Date:  1993-05-05       Impact factor: 5.157

Review 5.  The apparent uPA/PAI-1 paradox in cancer: more than meets the eye.

Authors:  Hau C Kwaan; Andrew P Mazar; Brandon J McMahon
Journal:  Semin Thromb Hemost       Date:  2013-03-26       Impact factor: 4.180

6.  The interaction between uPAR and vitronectin triggers ligand-independent adhesion signalling by integrins.

Authors:  Gian Maria Sarra Ferraris; Carsten Schulte; Valentina Buttiglione; Valentina De Lorenzi; Andrea Piontini; Massimiliano Galluzzi; Alessandro Podestà; Chris D Madsen; Nicolai Sidenius
Journal:  EMBO J       Date:  2014-08-28       Impact factor: 11.598

7.  Construction of a plasminogen activator inhibitor-1 variant without measurable affinity to vitronectin but otherwise normal.

Authors:  Jan K Jensen; Michelle K V Durand; Sune Skeldal; Daniel M Dupont; Julie S Bødker; Troels Wind; Peter A Andreasen
Journal:  FEBS Lett       Date:  2004-01-02       Impact factor: 4.124

8.  The urokinase receptor is a major vitronectin-binding protein on endothelial cells.

Authors:  S M Kanse; C Kost; O G Wilhelm; P A Andreasen; K T Preissner
Journal:  Exp Cell Res       Date:  1996-05-01       Impact factor: 3.905

9.  Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1.

Authors:  M V Cubellis; T C Wun; F Blasi
Journal:  EMBO J       Date:  1990-04       Impact factor: 11.598

10.  uPAR promotes formation of the p130Cas-Crk complex to activate Rac through DOCK180.

Authors:  Harvey W Smith; Pierfrancesco Marra; Christopher J Marshall
Journal:  J Cell Biol       Date:  2008-08-25       Impact factor: 10.539

View more
  10 in total

1.  Did evolution create a flexible ligand-binding cavity in the urokinase receptor through deletion of a plesiotypic disulfide bond?

Authors:  Julie M Leth; Haydyn D T Mertens; Katrine Zinck Leth-Espensen; Thomas J D Jørgensen; Michael Ploug
Journal:  J Biol Chem       Date:  2019-03-20       Impact factor: 5.157

2.  Arms race: diverse effector proteins with conserved motifs.

Authors:  Liping Liu; Le Xu; Qie Jia; Rui Pan; Ralf Oelmüller; Wenying Zhang; Chu Wu
Journal:  Plant Signal Behav       Date:  2019-01-09

3.  Vitronectin and Urokinase-Type Plasminogen Activator Gene Expression Levels Are Increased in Patients with Coronary Artery In-Stent Restenosis.

Authors:  S M Shafiee; F Noorabad-Ghahroodi; A Amirfarhangi; S R Hosseini-Fard; Z Sharifi; M Najafi
Journal:  Int J Angiol       Date:  2017-04-16

4.  Urokinase links plasminogen activation and cell adhesion by cleavage of the RGD motif in vitronectin.

Authors:  Valentina De Lorenzi; Gian Maria Sarra Ferraris; Jeppe B Madsen; Michela Lupia; Peter A Andreasen; Nicolai Sidenius
Journal:  EMBO Rep       Date:  2016-05-17       Impact factor: 8.807

5.  Fibronectin Facilitates Enterovirus 71 Infection by Mediating Viral Entry.

Authors:  Qiao-Qiao He; Sheng Ren; Zhang-Chuan Xia; Zhi-Kui Cheng; Nan-Fang Peng; Ying Zhu
Journal:  J Virol       Date:  2018-04-13       Impact factor: 5.103

6.  Increased soluble urokinase plasminogen activator receptor (suPAR) levels in neovascular age-related macular degeneration: a role for inflammation in the pathogenesis of the disease?

Authors:  Fabrizio Scotti; Paolo Milani; Marco Setaccioli; Silvia Maestroni; Nicolai Sidenius; Valentina De Lorenzi; Amedeo Massacesi; Fulvio Bergamini; Gianpaolo Zerbini
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-01-07       Impact factor: 3.117

Review 7.  Systems biology-opportunities and challenges: the application of proteomics to study the cardiovascular extracellular matrix.

Authors:  Javier Barallobre-Barreiro; Marc Lynch; Xiaoke Yin; Manuel Mayr
Journal:  Cardiovasc Res       Date:  2016-09-15       Impact factor: 10.787

8.  Plasminogen activator inhibitor-1 is an independent prognostic factor of ovarian cancer and IMD-4482, a novel plasminogen activator inhibitor-1 inhibitor, inhibits ovarian cancer peritoneal dissemination.

Authors:  Erika Nakatsuka; Kenjiro Sawada; Koji Nakamura; Akihito Yoshimura; Yasuto Kinose; Michiko Kodama; Kae Hashimoto; Seiji Mabuchi; Hiroshi Makino; Eiichi Morii; Yoichi Yamaguchi; Takeshi Yanase; Akiko Itai; Ken-Ichirou Morishige; Tadashi Kimura
Journal:  Oncotarget       Date:  2017-09-12

Review 9.  Modulation of Cellular Function by the Urokinase Receptor Signalling: A Mechanistic View.

Authors:  Daniela Alfano; Paola Franco; Maria Patrizia Stoppelli
Journal:  Front Cell Dev Biol       Date:  2022-04-08

10.  Personalised Approach to Diagnosing and Managing Ischemic Stroke with a Plasma-Soluble Urokinase-Type Plasminogen Activator Receptor.

Authors:  Katarzyna Śmiłowska; Marek Śmiłowski; Robert Partyka; Danuta Kokocińska; Przemysław Jałowiecki
Journal:  J Pers Med       Date:  2022-03-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.